Moreover, GLP-1 RAs have demonstrated cardiovascular benefits in high-risk patients, such as those with coronary syndromes, heart failure, or chronic kidney diseases, representing pharmacological progress in reducing the burden not only of diabetes mellitus but also of its complications [3]. The gene discussed is GLP1R; the disease is diabetes mellitus.